Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | TBXA2R | P21731 | 5/20 | 0.42 |
| ▸ | HSPB1 | P04792 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4236908 | 0.87 | HSPB1 (0.43) | MAPTMEN1KMT2ATBXA2RHSPB1 | |
| SCHEMBL4229107 | 0.87 | TBXA2R (0.42) | MAPTPOLBHTTMEN1KMT2A | |
| SCHEMBL4232035 | 0.83 | MAPT (0.46) | MAPTPOLBHTTMEN1KMT2A | |
| SCHEMBL4237839 | 0.83 | ALDH1A1 (0.44) | MAPTPOLBHTTMEN1KMT2A | |
| SCHEMBL4227934 | 0.79 | HSPB1 (0.53) | MAPTMEN1KMT2ATBXA2RHSPB1 | |
| SCHEMBL4240945 | 0.78 | ALDH1A1 (0.39) | MAPTHTTMEN1KMT2ATBXA2R | |
| SCHEMBL4232011 | 0.78 | HSPB1 (0.39) | MAPTHTTMEN1KMT2ATBXA2R | |
| SCHEMBL4238402 | 0.78 | TBXA2R (0.39) | MAPTHTTMEN1KMT2ATBXA2R | |
| SCHEMBL4242192 | 0.77 | PDE7A (0.52) | MAPTMEN1KMT2ATBXA2RSMN1; SMN2 | |
| SCHEMBL4237489 | 0.77 | TBXA2R (0.41) | MAPTHTTMEN1KMT2ATBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | NPY1R, NPY5R, NPY2R | MAPT 1398/4885POLB 4249/4885HTT 618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.